

Sarah A Holstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6865771/publications.pdf>

Version: 2024-02-01

122
papers

3,501
citations

236612

25
h-index

149479

56
g-index

125
all docs

125
docs citations

125
times ranked

3782
citing authors

#	ARTICLE	IF	CITATIONS
1	BIA 102474: Some Lessons are Clear but Important Questions Remain Unanswered. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 343-345.	2.3	3
2	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-13.	1.3	2
3	Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2022, 11, 5.	2.0	4
4	The Peptide“Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. <i>HemaSphere</i> , 2022, 6, e687.	1.2	3
5	Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2022, 13, 871-874.	0.5	9
6	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	2.8	5
7	A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-13.	1.1	3
8	Quantitative Clinical Pharmacology of CAR T“Cell Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 11-15.	2.3	2
9	Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20021-e20021.	0.8	8
10	Review: Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	3
11	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
12	Treatment Considerations for Transplant-Ineligible Multiple Myeloma. <i>Oncology</i> , 2021, 35, 170-182.	0.4	1
13	Melflufen: A Next-Generation Nitrogen Mustard. <i>Journal of Clinical Oncology</i> , 2021, 39, 836-839.	0.8	3
14	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
15	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. <i>Drugs</i> , 2021, 81, 825-840.	4.9	6
16	Future Directions in Maintenance Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2261.	1.0	8
17	In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway. <i>Pharmacological Research</i> , 2021, 167, 105528.	3.1	7
18	Visual dysfunction in a mouse model of chemotherapy-related neurotoxicity.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24059-e24059.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2021, 39, 7021-7021.	0.8	1
20	Impact of Î±-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 44, 116307.	1.4	7
21	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	0.6	3
22	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.	0.6	20
23	Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study. Blood, 2021, 138, 898-898.	0.6	10
24	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. Blood, 2021, 138, 2723-2723.	0.6	3
25	CAR Tâ€Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology and Therapeutics, 2020, 107, 112-122.	2.3	111
26	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
27	Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research. Neuro-Ophthalmology, 2020, 44, 139-147.	0.4	1
28	Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study. Journal of the Neurological Sciences, 2020, 410, 116644.	0.3	5
29	The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patientâ€Focused Precision Therapeutics. Clinical Pharmacology and Therapeutics, 2020, 108, 399-404.	2.3	3
30	Oncology Treatment in the Era of COVIDâ€19: We Cannot Afford to Hit the Pause Button. Clinical Pharmacology and Therapeutics, 2020, 108, 422-424.	2.3	2
31	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.	0.6	436
32	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
33	Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115604.	1.4	4
34	Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e239-e258.	0.2	6
35	Autologous Stem-Cell Transplantation for Myeloma: Here to Stay?. JCO Oncology Practice, 2020, 16, 67-68.	1.4	0
36	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	2.8	75

#	ARTICLE	IF	CITATIONS
37	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1414-1424.	2.0	5
38	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. <i>Bone Marrow Transplantation</i> , 2019, 54, 497-507.	1.3	11
39	¶-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126633.	1.0	8
40	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 889-898.	1.1	6
41	In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 327-338.	1.3	14
42	Novel benzimidazole phosphonates as potential inhibitors of protein prenylation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126757.	1.0	5
43	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 31-38.	1.2	15
44	A patent review of bisphosphonates in treating bone disease. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 315-325.	2.4	19
45	Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2019, 38, 5308-5320.	2.6	21
46	Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 39-46.	1.2	5
47	Modeling the Effects of Multiple Myeloma on Kidney Function. <i>Scientific Reports</i> , 2019, 9, 1726.	1.6	7
48	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e89-e97.	2.0	12
49	Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron. <i>Leukemia Research</i> , 2019, 77, 17-27.	0.4	6
50	Commentary on "œs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale. <i>Leukemia</i> , 2019, 33, 565-566.	3.3	2
51	Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 120-120.	0.6	7
52	In Vitro and inVivo Activity of Melflufen in Amyloidosis. <i>Blood</i> , 2019, 134, 3100-3100.	0.6	2
53	Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550). <i>Blood</i> , 2019, 134, 4451-4451.	0.6	5
54	Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4417-4417.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2155-2155.	0.6	0
56	The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience. <i>Blood</i> , 2019, 134, 2028-2028.	0.6	0
57	Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 22-28.	1.4	4
58	Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor. <i>Investigational New Drugs</i> , 2018, 36, 810-818.	1.2	15
59	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 11-20.	2.3	142
60	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 641-648.	2.0	19
61	±-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 376-385.	1.4	27
62	Present and Future of Immunotherapy in the Management of Multiple Myeloma. <i>Journal of Oncology Practice</i> , 2018, 14, 403-410.	2.5	8
63	Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. <i>Journal of Clinical Oncology</i> , 2018, 36, 2101-2104.	0.8	8
64	Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS. <i>Molecules</i> , 2018, 23, 3275.	1.7	18
65	Update on the role of lenalidomide in patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 175-190.	1.1	42
66	Electrophysiological Measure of Impaired Information Processing in Drivers with Hematological Malignancy. <i>Transportation Research Record</i> , 2018, 2672, 64-73.	1.0	8
67	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
68	Isoprenoid Amide Bisphosphonates As a Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors. <i>Blood</i> , 2018, 132, 4679-4679.	0.6	10
69	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq1 1 0.7843 t4rgBT /Overlock 10		
70	In Vivo Evaluation of Novel Geranylgeranyl Diphosphate Synthase Inhibitors. <i>Blood</i> , 2018, 132, 215-215.	0.6	1
71	Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8050-8050.	0.8	1
72	Effects of a temporal break between mobilization and conditioning on complications and hospitalization charges in multiple myeloma patients undergoing autologous stem cell transplant (ASCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20002-e20002.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Allogeneic Stem Cell Transplantation for Multiple Myeloma: A 34-Year Experience. <i>Blood</i> , 2018, 132, 5780-5780.	0.6	1
74	Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase. <i>Molecular Pharmacology</i> , 2017, 91, 229-236.	1.0	19
75	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. <i>Drugs</i> , 2017, 77, 505-520.	4.9	150
76	Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2437-2444.	1.4	21
77	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
78	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1975-1985.	0.9	10
79	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. <i>Blood Advances</i> , 2017, 1, 1056-1066.	2.5	40
80	Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors. <i>Molecules</i> , 2017, 22, 886.	1.7	26
81	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
82	Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. <i>Oncotarget</i> , 2017, 8, 76085-76098.	0.8	17
83	Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511.	0.9	22
84	Novel $\hat{\pm}$ -substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis. <i>Pharmacological Research</i> , 2016, 113, 438-448.	3.1	17
85	Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates. <i>Journal of Organic Chemistry</i> , 2016, 81, 9438-9442.	1.7	20
86	Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e129-e131.	0.2	13
87	A new motif for inhibitors of geranylgeranyl diphosphate synthase. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3734-3741.	1.4	14
88	Stereocontrolled regeneration of olefins from epoxides. <i>Tetrahedron Letters</i> , 2016, 57, 1335-1337.	0.7	7
89	Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. <i>Blood</i> , 2016, 128, 2274-2274.	0.6	1
90	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3454-3454.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Effects of Isoprenoid Biosynthetic Pathway Inhibition on Glucose Uptake in Myeloma Cells. <i>Blood</i> , 2016, 128, 3300-3300.	0.6	0
92	Synergistic Inhibition of Geranylgeranyl Diphosphate Synthase By a Mixture of Olefin Stereoisomers. <i>Blood</i> , 2016, 128, 2320-2320.	0.6	0
93	Continued role for ASCT in multiple myeloma. <i>Lancet Oncology</i> , The, 2015, 16, 1571-1573.	5.1	0
94	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 793-798.	2.0	23
95	Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 594-602.	1.2	6
96	N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2331-2334.	1.0	10
97	Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1195-1198.	1.3	38
98	Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. <i>Oncotarget</i> , 2015, 6, 41535-41549.	0.8	22
99	Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1113-1129.	0.9	4
100	Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2791-2798.	1.4	33
101	A Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors: Structure-Activity Relationships of Homoisoprenoid Triazoles in Myeloma Cells. <i>Blood</i> , 2014, 124, 2156-2156.	0.6	1
102	Triazole-based inhibitors of geranylgeranyltransferase II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 764-766.	1.0	25
103	Synthesis and Structure-Function Relationship Of Novel Triazole Phosphonates As Inhibitors Of Rab Geranylgeranyl Transferase. <i>Blood</i> , 2013, 122, 4223-4223.	0.6	0
104	Is there a future for prenyltransferase inhibitors in cancer therapy?. <i>Current Opinion in Pharmacology</i> , 2012, 12, 704-709.	1.7	26
105	Targeting Rab Geranylgeranylation Disrupts Myeloma-Stromal Cell Interactions. <i>Blood</i> , 2012, 120, 1354-1354.	0.6	0
106	Pleiotropic Effects of a Schweinfurthin on Isoprenoid Homeostasis. <i>Lipids</i> , 2011, 46, 907-921.	0.7	17
107	Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. <i>Leukemia Research</i> , 2011, 35, 551-559.	0.4	41
108	Evaluation of Autophagy Modulators and Isoprenoid Biosynthetic Pathway Inhibitors in Multiple Myeloma Cells. <i>Blood</i> , 2011, 118, 2488-2488.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. <i>Leukemia Research</i> , 2010, 34, 344-351.	0.4	19
110	Interaction Between Heat Shock Protein Inhibitors and Isoprenoid Biosynthetic Pathway Inhibitors In Multiple Myeloma Cells. <i>Blood</i> , 2010, 116, 2895-2895.	0.6	0
111	Quantitative Determination of Geranyl Diphosphate Levels in Cultured Human Cells. <i>Lipids</i> , 2009, 44, 1055-1062.	0.7	12
112	Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. <i>Leukemia Research</i> , 2009, 33, 344-347.	0.4	33
113	Biochemical Basis for Interactions Between Thalidomide and Inhibitors of the Isoprenoid Biosynthetic Pathway in Multiple Myeloma Cells. <i>Blood</i> , 2008, 112, 2635-2635.	0.6	0
114	Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 155-164.	1.1	69
115	Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. <i>Leukemia Research</i> , 2005, 29, 527-533.	0.4	34
116	Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. <i>Analytical Biochemistry</i> , 2005, 336, 51-59.	1.1	72
117	Isoprenoids: Remarkable diversity of form and function. <i>Lipids</i> , 2004, 39, 293-309.	0.7	206
118	Isoprenoid Pyrophosphate Analogues Regulate Expression of Ras-Related Proteins. <i>Biochemistry</i> , 2003, 42, 4384-4391.	1.2	23
119	Monoterpene regulation of Ras and Ras-related protein expression. <i>Journal of Lipid Research</i> , 2003, 44, 1209-1215.	2.0	34
120	Consequences of Mevalonate Depletion. <i>Journal of Biological Chemistry</i> , 2002, 277, 10678-10682.	1.6	84
121	Isoprenoids Influence Expression of Ras and Ras-Related Proteins. <i>Biochemistry</i> , 2002, 41, 13698-13704.	1.2	61
122	Interaction of cytosine arabinoside and lovastatin in human leukemia cells. <i>Leukemia Research</i> , 2001, 25, 651-660.	0.4	58